Clinical Trials

90 enrolled

Colorectal Neoplasms

NCT06562543 2026-05-20

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Phase 4 Recruiting

78 enrolled

Colorectal Neoplasms

NCT07136077 2026-05-15

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT06356584 2026-04-28

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT07042685 2026-04-09

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

50 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3 Recruiting

430 enrolled

Colorectal Neoplasms

NCT07011576 2026-03-18

FRUITFUL

60 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06992258 2026-03-17

FRUITION

120 enrolled

Colorectal Neoplasms

NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

68 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT07270991 2026-02-05

FRUQUITAS

Phase 3 Recruiting

324 enrolled

Tumor-Agnostic

Neoplasms

NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

594 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05954429 2026-01-22

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

50 enrolled

Colorectal Neoplasms

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

186 enrolled

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT07130903 2025-11-10

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

102 enrolled

Metastatic Colorectal Adenocarcinoma

NCT06441565 2025-07-30

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Phase 2/3 Recruiting

84 enrolled

Colorectal Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

70 enrolled

Metastatic Gastroesophageal Junction Adenocarcinoma

NCT05771181 2025-06-12

Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients

25 enrolled

Colorectal Neoplasms

NCT07003022 2025-06-04

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

40 enrolled

Colonic Neoplasms

NCT06980532 2025-05-20

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

42 enrolled

Colorectal Neoplasms

NCT05848739 2025-05-11

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase 1 Recruiting

130 enrolled

Colonic Neoplasms

NCT06791083 2025-01-24

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

40 enrolled

Stomach Neoplasms

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

66 enrolled

Fruquintinib

NCT06774222 2025-01-14

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

69 enrolled

Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3 Recruiting

412 enrolled

Gynecologic

Endometrial Neoplasms

NCT06446154 2024-12-31

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma

36 enrolled

Carcinoma, Hepatocellular

NCT06685276 2024-11-20

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

46 enrolled

Colorectal Cancer Metastatic

NCT06646588 2024-10-17

SJZ-RMEEC01

67 enrolled

Esophageal Neoplasms

NCT06613113 2024-09-25

Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

Phase NA Recruiting

30 enrolled

MSS Metastatic Colorectal Cancer

NCT06551207 2024-08-13

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Phase NA Recruiting

80 enrolled

Colorectal Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

68 enrolled

Colorectal Neoplasms

NCT06148402 2024-05-13

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT06234007 2024-03-18

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

45 enrolled

Colorectal Neoplasms

NCT06168786 2023-12-21

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

40 enrolled

Colorectal Neoplasms

NCT06091423 2023-11-30

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

43 enrolled

Stomach Neoplasms

NCT06118762 2023-11-07

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

Phase 4 Recruiting

30 enrolled

Colorectal Neoplasms

NCT06018714 2023-08-31

Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study

64 enrolled